Machine-learning-based integration of tumor microenvironment features predicting immunotherapy response

Abstract

Immunotherapy has revolutionized cancer treatment in recent years, yet non-responsiveness of immunotherapy remains a challenge for cancer treatment. Therefore, the prediction method for potential clinical benefits of patients from immunotherapy is urgently needed. This study aims to develop an effective clinical practice assistance tool to evaluate the potential clinical benefits and therapy responsiveness of patients undergoing immunotherapy. We developed an immunotherapy resistance score (IRS), which performed well compared with conventional immunotherapy response indicators across different immunotherapy cohorts. Tumor microenvironment (TME) analysis showed that both immune and nonimmune features collectively impact immunotherapy responsiveness. Thus, IRS was constructed based on the TME features using machine learning approaches. The clinical application potential of IRS has been demonstrated in our in-house Harbin Medical University (HMU) cohort and an external validation cohort. Furthermore, we analyzed the correlation between IRS and pathways related to cancer therapy targets to explore the application potential of IRS in comprehensive cancer therapy. In conclusion, IRS is a robust tool for predicting patient immunotherapy prognosis, which has great potential to promote precise clinical therapy.

Keywords

immunotherapy response / machine-learning / pan-cancer / tumor microenvironment

References

[1] RileyRS, JuneCH, LangerR, Mitchell MJ. Delivery technologies for cancer immunotherapy. Nat Rev Drug Discov. 2019; 18(3):175-196.

[2] QuesadaJ, HershE, ManningJ, et al. Treatment of hairy cell leukemia with recombinant alpha-interferon. Blood. 1986; 68(2):493-497.

[3] RibasA, Wolchok JD. Cancer immunotherapy using checkpoint blockade. Science. 2018; 359(6382):1350-1355.

[4] HodiFS, Chiarion-Sileni V, GonzalezR, et al. Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067):4-year outcomes of a multicentre, randomised, phase 3 trial. Lancet Oncol. 2018; 19(11):1480-1492.

[5] JuneCH, O’Connor RS, KawalekarOU, GhassemiS, MiloneMC. CAR T cell immunotherapy for human cancer. Science. 2018; 359(6382):1361-1365.

[6] AlwanLM, Grossmann K, SageserD, Van AttaJ, Agarwal N, GilreathJA. Comparison of acute toxicity and mortality after two different dosing regimens of high-dose interleukin-2 for patients with metastatic melanoma. Target Oncol. 2014; 9(1):63-71.

[7] ChamotoK, Al-Habsi M, HonjoT. Role of PD-1 in immunity and diseases. Curr Top Microbiol Immunol. 2017; 410:75-97.

[8] IwaiY, Hamanishi J, ChamotoK, HonjoT. Cancer immunotherapies targeting the PD-1 signaling pathway. J Biomed Sci. 2017; 24(1):26.

[9] BritoABC, Camandaroba MPG, de LimaVCC. Anti-PD1 versus anti-PD-L1 immunotherapy in first-line therapy for advanced non-small cell lung cancer: a systematic review and meta-analysis. Thorac Cancer. 2021; 12(7):1058-1066.

[10] ReinkeS, Bröckelmann PJ, IaccarinoI, et al. Tumor and microenvironment response but no cytotoxic T-cell activation in classic hodgkin lymphoma treated with anti-PD1. Blood. 2020; 136(25):2851-2863.

[11] MariathasanS, TurleySJ, NicklesD, et al. TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells. Nature. 2018; 554(7693):544-548.

[12] StoneJB, DeAngelis LM. Cancer-treatment-induced neurotoxicity--focus on newer treatments. Nat Rev Clin Oncol. 2016; 13(2):92-105.

[13] O’DonnellJS, Teng MWL, SmythMJ. Cancer immunoediting and resistance to T cell-based immunotherapy. Nat Rev Clin Oncol. 2019; 16(3):151-167.

[14] PoznanskiSM, Ritchie TM, FanIY, et al. Expanded human NK cells from lung cancer patients sensitize patients’ PDL1-negative tumors to PD1-blockade therapy. J Immunother Cancer. 2021; 9(1):e001933.

[15] HornL, SpigelDR, VokesEE, et al. Nivolumab versus docetaxel in previously treated patients with advanced non-small-cell lung cancer: two-year outcomes from two randomized, open-label, phase III trials (CheckMate 017 and CheckMate 057). J Clin Oncol. 2017; 35(35):3924-3933.

[16] KennedyLB, SalamaAKS. A review of cancer immunotherapy toxicity. CA Cancer J Clin. 2020; 70(2):86-104.

[17] ChanTA, Yarchoan M, JaffeeE, et al. Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic. Ann Oncol. 2019; 30(1):44-56.

[18] WangP, ChenY, WangC. Beyond tumor mutation burden: tumor neoantigen burden as a biomarker for immunotherapy and other types of therapy. Front Oncol. 2021; 11:672677.

[19] ChenDS, Mellman I. Elements of cancer immunity and the cancer-immune set point. Nature. 2017; 541(7637):321-330.

[20] StricklerJH, HanksBA, KhasrawM. Tumor mutational burden as a predictor of immunotherapy response: is more always better. Clin Cancer Res. 2021; 27(5):1236-1241.

[21] CouliePG, Van den Eynde BJ, van der BruggenP, BoonT. Tumour antigens recognized by T lymphocytes: at the core of cancer immunotherapy. Nat Rev Cancer. 2014; 14(2):135-146.

[22] MaltaTM, Sokolov A, GentlesAJ, et al. Machine learning identifies stemness features associated with oncogenic dedifferentiation. Cell. 2018; 173(2):338-354.e15.

[23] Comprehensive molecular characterization of urothelial bladder carcinoma. Nature. 2014; 507(7492):315-322.

[24] MaS, MengZ, ChenR, Guan KL. The hippo pathway: biology and pathophysiology. Annu Rev Biochem. 2019; 88:577-604.

[25] FuM, HuY, LanT, GuanKL, LuoT, LuoM. The Hippo signalling pathway and its implications in human health and diseases. Signal Transduct Target Ther. 2022; 7(1):376.

[26] MengZ, Moroishi T, GuanKL. Mechanisms of Hippo pathway regulation. Genes Dev. 2016; 30(1):1-17.

[27] MorrisonAH, ByrneKT, VonderheideRH. Immunotherapy and prevention of pancreatic cancer. Trends Cancer. 2018; 4(6):418-428.

[28] ZhangY, ZhangZ. The history and advances in cancer immunotherapy: understanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications. Cell Mol Immunol. 2020; 17(8):807-821.

[29] ArinaA, Gutiontov SI, WeichselbaumRR. Radiotherapy and immunotherapy for cancer: from “systemic” to “multisite. Clin Cancer Res. 2020; 26(12):2777-2782.

[30] JohannetP, Coudray N, DonnellyDM, et al. Using machine learning algorithms to predict immunotherapy response in patients with advanced melanoma. Clin Cancer Res. 2021; 27(1):131-140.

[31] WangZ, WangY, YangT, et al. Machine learning revealed stemness features and a novel stemness-based classification with appealing implications in discriminating the prognosis, immunotherapy and temozolomide responses of 906 glioblastoma patients. Brief Bioinform. 2021; 22(5):bbab032.

[32] CharoentongP, Finotello F, AngelovaM, et al. Pan-cancer immunogenomic analyses reveal Genotype-Immunophenotype relationships and predictors of response to checkpoint blockade. Cell Rep. 2017; 18(1):248-262.

[33] BaoX, ShiR, ZhaoT, et al. Integrated analysis of single-cell RNA-seq and bulk RNA-seq unravels tumour heterogeneity plus M2-like tumour-associated macrophage infiltration and aggressiveness in TNBC. Cancer Immunol Immunother. 2021; 70(1):189-202.

[34] CaoR, MaB, WangG, Xiong Y, TianY, YuanL. Characterization of hypoxia response patterns identified prognosis and immunotherapy response in bladder cancer. Mol Ther Oncolytics. 2021; 22:277-293.

[35] BattramAM, Bachiller M, Martín-AntonioB. Senescence in the development and response to cancer with immunotherapy: a double-edged sword. Int J Mol Sci. 2020; 21(12):4346.

[36] ChenX, KangR, KroemerG, Tang D. Broadening horizons: the role of ferroptosis in cancer. Nat Rev Clin Oncol. 2021; 18(5):280-296.

[37] DengL, JiangA, ZengH, Peng X, SongL. Comprehensive analyses of PDHA1 that serves as a predictive biomarker for immunotherapy response in cancer. Front Pharmacol. 2022; 13:947372.

[38] KeenanBP, FongL, KelleyRK. Immunotherapy in hepatocellular carcinoma: the complex interface between inflammation, fibrosis, and the immune response. J Immunother Cancer. 2019; 7(1):267.

[39] GalonJ, BruniD. Approaches to treat immune hot, altered and cold tumours with combination immunotherapies. Nat Rev Drug Discov. 2019; 18(3):197-218.

[40] Garcia GarciaCJ, HuangY, FuentesNR, et al. Stromal HIF2 regulates immune suppression in the pancreatic cancer microenvironment. Gastroenterology. 2022; 162(7):2018-2031.

[41] JiangY, ZhanH. Communication between EMT and PD-L1 signaling: new insights into tumor immune evasion. Cancer Lett. 2020; 468:72-81.

[42] HanahanD. Hallmarks of cancer: new dimensions. Cancer Discovery. 2022; 12(1):31-46.

[43] NansenC, Geremias LD, XueY, HuangF, ParraJR. Agricultural case studies of classification accuracy, spectral resolution, and model over-fitting. Appl Spectrosc. 2013; 67(11):1332-1338.

[44] MiočevićM, MacKinnonDP, LevyR. Power in Bayesian mediation analysis for small sample research. Struct Equ Modeling. 2017; 24(5):666-683.

[45] RafiqueR, IslamSMR, KaziJU. Machine learning in the prediction of cancer therapy. Comput Struct Biotechnol J. 2021; 19:4003-4017.

[46] BarretinaJ, Caponigro G, StranskyN, et al. The cancer cell line encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature. 2012; 483(7391):603-607.

[47] ArashiM, Roozbeh M, HamzahNA, GaspariniM. Ridge regression and its applications in genetic studies. PLoS One. 2021; 16(4):e0245376.

[48] HänzelmannS, Castelo R, GuinneyJ. GSVA: gene set variation analysis for microarray and RNA-seq data. BMC Bioinformatics. 2013; 14:7.

[49] GideTN, QuekC, MenziesAM, et al. Distinct immune cell populations define response to anti-PD-1 monotherapy and anti-PD-1/anti-CTLA-4 combined therapy. Cancer Cell. 2019; 35(2):238-255.e6.

[50] EngebretsenS, BohlinJ. Statistical predictions with glmnet. Clin Epigenetics. 2019; 11(1):123.

[51] NewmanAM, SteenCB, LiuCL, et al. Determining cell type abundance and expression from bulk tissues with digital cytometry. Nat Biotechnol. 2019; 37(7):773-782.

[52] YoshiharaK, Shahmoradgoli M, MartínezE, et al. Inferring tumour purity and stromal and immune cell admixture from expression data. Nat Commun. 2013; 4:2612.

RIGHTS & PERMISSIONS

2025 The Author(s). MedComm – Future Medicine published by John Wiley & Sons Australia, Ltd on behalf of Sichuan International Medical Exchange & Promotion Association (SCIMEA).